Emerging Drugs and Combination Strategies for Basal Cell Carcinoma
April 2014
in “
Expert opinion on emerging drugs
”
TLDR New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
The document reviewed emerging drugs and combination strategies for treating basal cell carcinoma (BCC). It highlighted the development of targeted therapies, particularly focusing on the Hedgehog signaling pathway inhibitors like vismodegib and sonidegib, which showed promise in treating advanced BCC. The authors discussed the potential benefits of combining these inhibitors with other treatments, such as radiotherapy and immunotherapy, to enhance efficacy and reduce resistance. The review emphasized the need for ongoing research to optimize these combination strategies and improve patient outcomes.
